Alternatives for microdosing GLP-1 medications include a slower titration phase, switching to a different medication, or managing the side effects with lifestyle modifications

44 46 , 50 Figure 2Evidence Network for Change in A1C and Weight at 24 Weeks for NMA of Semaglutide Versus Other GLP-1 Agonists FIGURE CONTAINED CONFIDENTIAL INFORMATION AND WAS REDACTED AT THE REQUEST OF THE MANUFACTURER Figure 3Evidence Network for Change in A1C and Weight at 52 Weeks for NMA of Semaglutide Versus Other GLP-1 Agonists FIGURE CONTAINED CONFIDENTIAL INFORMATION AND WAS REDACTED AT THE REQUEST OF THE MANUFACTURER Table 59NMA Results for Change From Baseline in A1C for GLP-1 Agonists Table 60NMA Results for Change from Baseline in Weight (kg) for GLP-1 Agonists Results of Indirect Treatment Comparison for Semaglutide Versus SGLT2 Inhibitors as Add-On to Metformin Objective The objective of this indirect treatment comparison (ITC) was to assess the relative efficacy and safety of once-weekly semaglutide compared with sodium-glucose cotransporter-2 (SGLT2) inhibitors for the treatment of adults with type 2 diabetes who were inadequately controlled with metformin

1 - 13 An interesting point is the local cream application in wound studies (local cream application heals deep skin burns much like stress gastric lesions in mice)
Reconstituted solutions may have reduced stability and should be handled according to laboratory best practices
Under national pharmacare bilateral agreements, Health Canada will support British Columbia, Manitoba, Prince Edward Island and Yukon in providing free or lowcost contraception and diabetes medications through initiatives such as the Diabetes Devices and Supplies Fund and the Universal Access to Contraception and Diabetes Medications Initiative